Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Watzlawik JO, Wootla B, Painter MM, Warrington AE, Rodriguez M.

Expert Rev Neurother. 2013 Sep;13(9):1017-29. doi: 10.1586/14737175.2013.835601. Review.

2.

Method of identifying natural antibodies for remyelination.

Warrington AE, Rodriguez M.

J Clin Immunol. 2010 May;30 Suppl 1:S50-5. doi: 10.1007/s10875-010-9406-5.

3.

Remyelination-promoting human IgMs: developing a therapeutic reagent for demyelinating disease.

Warrington AE, Rodriguez M.

Curr Top Microbiol Immunol. 2008;318:213-39. Review.

PMID:
18219820
4.

Naturally occurring antibodies as therapeutics for neurologic disease: can human monoclonal IgMs replace the limited resource IVIG?

Warrington AE, Van Keulen V, Pease LR, Rodriguez M.

Adv Exp Med Biol. 2012;750:44-55. doi: 10.1007/978-1-4614-3461-0_4.

PMID:
22903665
5.

Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination.

Asakura K, Miller DJ, Pease LR, Rodriguez M.

J Neurosci. 1998 Oct 1;18(19):7700-8.

6.

Multi-faceted role of naturally occurring autoantibodies in fighting pathogens.

Bouhlal H, Kaveri S.

Adv Exp Med Biol. 2012;750:100-13. doi: 10.1007/978-1-4614-3461-0_8. Review.

PMID:
22903669
7.

Naturally occurring IgM antibodies to oxidation-specific epitopes.

Binder CJ.

Adv Exp Med Biol. 2012;750:2-13. doi: 10.1007/978-1-4614-3461-0_1.

PMID:
22903662
8.
9.
10.

The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment.

Wootla B, Watzlawik JO, Denic A, Rodriguez M.

Expert Rev Clin Immunol. 2013 Jun;9(6):535-49. doi: 10.1586/eci.13.37. Review.

PMID:
23730884
11.

Invited article: human natural autoantibodies in the treatment of neurologic disease.

Rodriguez M, Warrington AE, Pease LR.

Neurology. 2009 Apr 7;72(14):1269-76. doi: 10.1212/01.wnl.0000345662.05861.e4. Review.

12.

Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.

Wootla B, Watzlawik JO, Warrington AE, Wittenberg NJ, Denic A, Xu X, Jordan LR, Papke LM, Zoecklein LJ, Pierce ML, Oh SH, Kantarci OH, Rodriguez M.

JAMA Neurol. 2015 Nov;72(11):1346-53. doi: 10.1001/jamaneurol.2015.2188. Review.

PMID:
26389734
13.

Immune promotion of central nervous system remyelination.

Rodriguez M, Miller DJ.

Prog Brain Res. 1994;103:343-55. Review.

PMID:
7886217
14.

Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination.

Pavelko KD, van Engelen BG, Rodriguez M.

J Neurosci. 1998 Apr 1;18(7):2498-505.

15.

Antibody-mediated remyelination: relevance to multiple sclerosis.

Bieber A, Asakura K, Warrington A, Kaveri SV, Rodriguez M.

Mult Scler. 2000 Oct;6 Suppl 2:S1-5; discussion S33. Review.

PMID:
11188771
16.

Naturally occurring autoantibodies to apoptotic cells.

Elkon KB, Silverman GJ.

Adv Exp Med Biol. 2012;750:14-26. doi: 10.1007/978-1-4614-3461-0_2.

PMID:
22903663
17.

Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function.

Ciric B, Howe CL, Paz Soldan M, Warrington AE, Bieber AJ, Van Keulen V, Rodriguez M, Pease LR.

Brain Pathol. 2003 Oct;13(4):608-16.

PMID:
14655764
18.

Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair.

Paz Soldán MM, Warrington AE, Bieber AJ, Ciric B, Van Keulen V, Pease LR, Rodriguez M.

Mol Cell Neurosci. 2003 Jan;22(1):14-24.

PMID:
12595235
19.

Primary structure of the antigen-binding domains of a human oligodendrocyte-reactive IgM monoclonal antibody derived from a patient with multiple sclerosis.

Kirschning E, Jensen K, Dübel S, Rutter G, Hohenberg H, Will H.

J Neuroimmunol. 1999 Sep 1;99(1):122-30.

PMID:
10496185
Items per page

Supplemental Content

Support Center